Analogic — Merger or Acquisition (April 2018)
11 slides from Analogic's merger presentation, Apr 10, 2018
Slide 1: Analogic to be Acquired by Altaris Capital Partners
April 10, 2018 ANALOGIC TO BE ACQUIRED BY ALTARIS CAPITAL PARTNERS Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this presentation regarding the proposed transaction between Altaris Capital Partners, LLC (including affiliated entities, “Altaris”) and Analogic, the expected timetable for completing the transaction, future financial and operating results, benefits and syn
Slide 3: Focused on Providing Maximum Value for Analogic Stockholders
Focused on Providing Maximum Value for Analogic Stockholders Altaris transaction presents best combination of certainty and value for stockholders Conducted 10-month, comprehensive review of strategic alternatives available to Analogic Long-term Analogic outlook requires need for greater scale to ge
Slide 4: Catalysts for Strategic Review Process
Larger and better capitalized competitors Long-term macroeconomic trends in medical imaging Continued strategic investments New channels to market Need for greater scale Increasing global competition Catalysts for Strategic Review Process Internal & External Business Considerations
Slide 5: Overview of Strategic Review Process
Following review of the alternatives with financial and legal advisors, the Board determined that the Altaris transaction presented the best combination of certainty and value for stockholders. Strategic review process was comprehensive and lasted for approximately 10-months. Process was led by a St
Slide 6: Range of Alternatives Considered
Sale of Entire Company Range of Alternatives Considered Separating Businesses Immediate and substantial value for all stockholders; Board unanimously recommends transaction Tax leakage and stranded costs; execution risk Continued Operation on Standalone Basis—Short- and Long-term Need for greater sc
Slide 7: Best Combination of Value & Certainty
Best Combination of Value & Certainty Per Share Offer $84.00 per share, 100% cash Transaction Value Approximately $1.1 billion, on a fully diluted basis Premium 25% premium to Analogic’s closing share price of $67.45 on June 7, 2017, the day after the Company reported quarterly earnings for the thir
Slide 8: Altaris Overview
Overview Established in 2003 Deep expertise in the medical device and diagnostic equipment industries, including imaging technologies Analogic would represent 17th platform company to design and manufacture high value, FDA-regulated medical products and components Invested in 34 companies spanning s
Slide 9: Focused on Providing Maximum Value for Analogic Stockholders
Long-term Analogic outlook requires need for greater scale to generate sustained profitable growth in increasingly competitive markets Focused on Providing Maximum Value for Analogic Stockholders Conducted 10-month, comprehensive review of strategic alternatives available to Analogic Evaluated varie
Slide 10: Important Additional Information
Important Additional Information Analogic plans to file with the Securities and Exchange Commission (the “SEC”) and mail to its stockholders a Proxy Statement in connection with the transaction. The Proxy Statement will contain important information about Altaris, Analogic, the transaction and relat
Slide 11: Analogic
analogic |